

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 2

RECEIVED
CENTRAL FAX CENTER
NOV 25 2008

Amendments to the Claims

Please amend claims 16-19 under the provisions of 37 C.F.R. §1.121, as set forth in the Federal Register on June 30, 2003, as follows:

Claims 1-12. (Canceled)

13. (Previously Presented) A hydrate form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
14. (Canceled)
15. (Canceled)
16. (Currently Amended) A pharmaceutical composition comprising from about 0.001 mg—to about 100 mg per kg body weight per day of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate or of a hydrate form of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate, and a pharmaceutically acceptable carrier.
17. (Currently Amended) The pharmaceutical composition of claim 16, comprising from about 1 mg—to about 35 mg/kg/day of the compound.
18. (Currently Amended) ~~The~~ A pharmaceutical composition ~~of claim 16,~~ comprising from about 0.05 mg—to about 7 g/day

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 3

of the compound of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate or of a hydrate form of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate, and a pharmaceutically acceptable carrier.

19. (Currently Amended) The pharmaceutical composition of claim ~~17~~ 18, comprising from about 0.2 g to about 2.5 g/day of the compound.
20. (Previously Presented) The pharmaceutical composition of claim 19, in the form of a tablet, capsule, pill, powder, sustained release formulations, solution, parenteral injection as a sterile solution, suspension or emulsion, or suppository.
21. (Previously Presented) The pharmaceutical composition of claim 20, in the form of a parenteral injection.
22. (Previously Presented) The pharmaceutical composition of claim 20, in the form of a tablet.
23. (Previously Presented) A method of treating a mammal suffering from a hyperproliferative disorder which comprises administering to said mammal an amount of the pharmaceutical composition of claim 16 therapeutically effective to inhibit the epidermal growth factor receptor ("EGFR") in the mammal, so as to thereby treat the mammal, wherein the hyperproliferative disorder is lung

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 4

cancer, breast cancer, ovarian cancer, prostate cancer,
or colorectal cancer.

24. (Canceled)

25. (Previously Presented) The method of claim 23 further comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, anti-hormones, and anti-androgens.

26. (Previously Presented) The method of claim 25 wherein the cell-cycle inhibitor is a mitotic inhibitor.

27. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 mg to about 100 mg of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

28. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 mg to about 100 mg of a hydrate form of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.